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Treatments administered with more convenient devices such as DPIs and shorter 
administration times are associated with higher utility and higher stated adherence 
in adult and pediatric patients.
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Objectives: Fatigue is one of the most frequent symptoms in patients with 
multiple sclerosis (MS). This study aimed to examine the severity and impact 
of fatigue in MS Brazilian patients. MethOds: This was a cross-sectional, mul-
ticenter study conducted in 8 Brazilian major MS treatment sites. Fatigue was 
assessed using the Brazilian version of the Modified Fatigue Impact Scale (MFIS), 
which evaluates the impact of fatigue on 3 dimensions of patients’ daily life: 
physical, cognitive and psychosocial. The patient scores 0 (lower impact) to 84 
points (higher impact). The final score was classified according to the level of 
impact: absent (0-38), low (39-58), and high (> 58). Results: The study enrolled 
210 MS patients, of which the mean age was 40.7 [standard deviation = 11.5] years 
and 70.7% were female. Patients with mild disability (according to self-reported 
Expanded Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% 
had moderate disability and 15.9% had severe disability. In the overall sample, 
the impact of fatigue was considered absent, low and high in 49%, 32% and 19% 
of patients, respectively. Any impact (both low and high summed) was reported 
by 33%, 63%, and 66% of patients with mild, moderate and severe disability, 
respectively. The mean MFIS total score for mild, moderate and severe patients 
was 29.3, 45.0, and 45.4 (38.6 in the total sample). The mean impact scores for 
each domain in the total sample were 20.0 (physical, range 0-36), 14.7 (cogni-
tive, range 0-40), and 3.9 (psychosocial, range 0-8), meaning that fatigue has a 
proportionally higher impact in the physical than the cognitive or psychosocial 
domains. cOnclusiOns: Our findings indicate that over 50% of MS Brazilian 
patients notice some adverse impact of fatigue in their daily lives, particularly 
related to the physical domain.
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Objectives: To measure the health-related quality of life (HRQL) of multiple 
sclerosis (MS) patients and examine potential associations between HRQL and 
patients’ characteristics. MethOds: This was a cross-sectional, multicenter study 
conducted in 8 Brazilian major MS treatment sites. HRQL was assessed using the 
Brazilian version of the EQ-5D and patients self-evaluated their HRQL and health 
status using five dimensions (mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression) and a visual analog scale (VAS). The EQ-5D index 
was calculated based on the value set derived from the UK population, since the 
Brazilian value set is not available. Results: The study enrolled 210 MS patients, 
of which the mean age (standard deviation [SD]) was 40.7 [11.5] years and 70.7% 
were female. Patients with mild disability (according to self-reported Expanded 
Disability Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate 
disability and 15.9% had severe disability. Among the 5 assessed HRQL dimensions, 
the ones with higher frequency of self-reported severe limitations were usual 
activities and anxiety/depression (11.0% each). The least impaired dimension was 
self-care, with 63.0% of patients reporting absence of limitation. The mean [SD] VAS 
score was 71.6 [18.9]. The mean EQ-5D index for each level of EDSS (mild, moder-
ate or severe disability) was 0.73 [0.21], 0.49 [0.30], and 0.30 [0.34], respectively. 
In the multivariate analysis, variables related to patients’ characteristics were 
explored and the following were associated with the presence of any limitation 
in at least one dimension: older age, unemployment/retirement, relapses in the 
previous year, emergency department visits in the previous 6 months and lower 
educational level. cOnclusiOns: MS adversely impact patients’ HRQL, especially 
with disability progression and clinical features that can be linked to more severe 
disease.
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Objectives: To conduct a systematic review of literature in peer-reviewed jour-
nals on real world treatment patterns and clinical trials on patients diagnosed 
with Insomnia. MethOds: A comprehensive literature search was performed 
using relevant search terms to identify articles published from 2000 to 2010 on 
the real world treatment patterns and clinical trials conducted on patients with 
Insomnia. Studies were identified through electronic Embase, Cochrane, Medline, 
and PubMed databases. Additional parameters were placed on the final search 
strategy to limit the retrieval to articles written in English, involving human sub-
jects. Results: Our search yielded 1,153 articles for treatment patterns and clini-
cal trials on patients diagnosed with Insomnia from PubMed/Medline/Embase/
Cochrane databases. After removing duplicates and non-relevant articles, 65 
articles were included for final review. A total of 16 studies had some focus on 
44mcg was chosen as comparator since it is the most widely prescribed disease 
modifying therapy for 1st-line treatment in HARRMS patients in Brazil. MethOds: 
We developed a Markov model with 20-year time horizon comparing natalizumab 
to IFNB1a 44mcg. Health states were based on EDSS and relapses (moderate or 
severe). Since there are no published data evaluating long-term course specifically 
in HARRMS, we assumed transition probabilities on EDSS states based on natural 
history studies on unselected RRMS patients, and relapse probabilities based on 
a post-hoc analysis of the pivotal natalizumab AFFIRM trial. This is a rather con-
servative approach, since disability progression may be slower in this proposed 
model then expected for patients with HARRMS and so the benefit from natali-
zumab could be underappreciated. In each monthly cycle, patients can discontinue 
treatment, remain stable, progress to higher EDSS state, experience Progressive 
Multifocal Leukoencephalopathy or die. Patients with EDSS score≥ 7.5 receive best 
supportive care. Resource use and costs were validated by an expert’s panel and 
valued using Brazilian public official lists (DATASUS and BPS). Costs and outcomes 
were discounted (5%). Probabilistic sensitivity analyses (PSA) covered variability in 
efficacy and costs. Results: Use of natalizumab was associated with slower EDSS 
progression and reduced relapse burden. Life years gained with natalizumab and 
IFNB1a 44mcg were 10.90 and 10.54, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus IFNB1a 44mcg. 
PSA has confirmed the consistency of results. cOnclusiOns: For a patient with 
HARRMS, the model shows that natalizumab was dominant when compared to 
IFNB1a 44mcg in the Brazilian Public Healthcare System.
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Objectives: To assess the health care resource utilization (HRU) of Brazilian mul-
tiple sclerosis (MS) patients. MethOds: This was a cross-sectional, multicenter 
study conducted in 8 Brazilian major MS treatment sites. HRU was evaluated as 
the percentage of patients self-reporting the consumption of resources. The main 
categories were: hospitalization, consultations, laboratory and imaging tests, dis-
ease modifying therapies (DMTs), co-medication, aidsand/or home modifications. 
Frequency and average consumption were annualized. Results: The study enrolled 
210 MS patients, mean age was 40.7 [standard deviation= 11.5] years and 70.7% 
female. Patients with mild disability (according to self-reported Expanded Disability 
Status Scale [EDSS]) represented 40.4% of patients, 43.7% had moderate disability 
and 15.9% had severe disability.Hospitalization was reported by 23%, 33% and 15% 
of mild, moderate and severe MS patients, with average length of stay of: 7.53, 10.41, 
and 7.40 days, respectively. Most patients (> 96%) had at least one neurologist con-
sultation per year (average 4.94 visits/year in the total sample). Physical therapy was 
the most consumed non-medical consultation (mild: 11%; moderate: 38%; severe: 
64%). Magnetic resonance imagingwas reported by 60%, 68%, and 55% of mild, mod-
erate and severe patients. Patients using at least one DMT during the previous year 
were: 89%, 93%, and 61% of mild, moderate and severe MS patients, respectively. 
The most prescribed DMT was glatiramer acetate (38%, total sample). The most fre-
quent co-medications were: anti-depressants, anti-spasticity, and analgesics. Home 
modification was reported by 19% and 45% of patients with moderate and severe 
disability, respectively. For ambulation, walking stick was used by 35% of moderate 
patients, while wheelchair was needed by 58% of severe patients. cOnclusiOns: To 
our knowledge, this is the first Brazilian study investigating the HRU of MS patients. 
The findings can be useful to better understand MS patients’ needs in terms of 
comprehensive care.
Neurological DiSorDerS – Patient-reported outcomes & Patient Preference 
Studies
PND14
wHicH cyStic fiBroSiS iNHaleD aNtiBiotic MeDiciNe featureS Matter 
MoSt to aDult PatieNtS aND PareNtS of PeDiatric PatieNtS?
Mohamed A.F.1, Johnson F.R.1, Balp M.M.2, Calado F.2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland
Objectives: To quantify patient and parent preferences and adherence for dif-
ferent administration features of inhaled antibiotic medicines for cystic fibrosis 
(CF). MethOds: Adult patients with a self-reported physician diagnosis of CF and 
parents of pediatric CF patients (6 to 17 years) who had Pseudomonas aeruginosa in 
their lung culture at least twice in one year completed a web-enabled, discrete-
choice experiment survey in the United States. Respondents answered 5 treat-
ment-choice questions with known statistical properties. Each question required 
evaluating a pair of hypothetical CF treatment profiles defined by device type (nebu-
lizer, dry powder inhaler (DPI)), total daily administration and cleaning time, dosing 
frequency, dry cough side effect, and personal cost per cycle. Lung function meas-
ured as forced expiratory volume in one second (FEV1) was held constant between 
the hypothetical CF treatment profiles. Stated adherence questions followed two 
randomly selected treatment-choice questions. Random-parameters logit models 
were used to estimate preference weights for all feature levels and the mean rela-
tive importance of each feature for both samples. Results: A total of 209 adult 
patients and 271 parents completed the survey. Mean age of adult patients was 32 
(SD = 10) years and mean age of pediatric patients was 12 (SD = 3) years. Among 
all respondents, the average time spent taking inhaled antibiotic medicines was 
approximately 40 minutes. Relative importance estimates indicated that switching 
from a 30-minute nebulizer twice daily to a 10-minute DPI twice daily was 6.3 times 
more important for adult patients and 2.0 times more important for parents than an 
improvement in dry cough from moderate to mild. Stated adherence for adult and 
pediatric patients was 20-30% higher for DPIs versus nebulizers. cOnclusiOns: 
